Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020

• Главные авторы: Joshua A. Jacobs (Автор), Alexander R. Zheutlin (Автор), Catherine G. Derington (Автор), Jordan B. King (Автор), Ambarish Pandey (Автор), Adam P. Bress (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2024-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Objective: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2Is) lower adverse cardiac and kidney events among high-risk patients with diabetes mellitus (DM) and are now guideline-recommended as first-line therapy alongside metformin. However, t...